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Nanomedicines employ multiple endocytic pathways to enter cells. Their following fate is
interesting, but it is not sufficient understood currently. This review introduces the
endocytic pathways, presents new technologies to confirm the specific endocytic pathways
and discusses factors for pathway selection. In addition, some intriguing implication about
nanomedicine design based on endocytosis will also be discussed at the end. This review
may provide new thoughts for the design of novel multifunctional nanomedicines.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction high concentration at the lesion site, excess drugs are taken.With the continuous development and progress of human
society, people are suffering much more modern diseases
than before. Tumors, for example, are characterized by
heterogeneity and adaptive resistance. Regarding tradi-
tional drugs, they work while trafficking in the blood cir-
culation and the concentration at the lesion site determines
the therapeutic efficacy of the drugs. Usually, to achievement of Biopharmaceutic
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der of other organic or tissular function would appear. It
was an inevitable problem for pharmaceutical scientists to
solve until nanomedicines emerge. Compared to traditional
small molecule drugs, theoretically speaking, nano-
medicines can concentrate at certain organs, tissues and
even cells, load more drugs to final targets, deliver macro-
molecules (like proteins and peptides) and minimize sides, School of Pharmacy, Shenyang Pharmaceutical University, No.
1.
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Fig. 1 e Nanoparticles internalization pathways in
mammalian cells. The picture briefly shows the
classification of endocytic trafficking and different
mechanisms of endocytosis. Abbreviation is: CCV, clathrin
coated vesicle.
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nanomedicine.
A series of nano-sized preparations, such as liposomes,
nanoparticles, polymeric micelles and polymeric-drug conju-
gates, have been developed in laboratory, and some of themare
undertaking preclinical studies. Some successful nano-sized
preparations have already emerged in today’s pharmaceutical
market and shown better clinical performance than traditional
drugs [2]. Traditional drugs with small molecule enter cells
mainly through the passive diffusion or active transport while
nanomedicines come into cells via endocytosis. Endocytosis
helps nanomedicines to enter specific cells and accumulate
there. Pharmaceutical scientists showed a great interest in this
process and spent much time and energy to study, and they
have obtained some achievements. The endocytosis pathway
has been classified according to the proteins which play a role
in the process. Correspondingly, it has been explained that how
nanomedicines interact with cytomembrane, enter cells and
travel in the cells in different pathways. Even so, there are still
many problems that have not been solved. Some pathways are
still insufficiently understood, and the functions of some pro-
teins involved in endocytosis are still uncertain, and the factors
that affect the pathway for nanomedicines entering cells are
not absolutely proven, etc. It is necessary to study further for a
better understanding, and the findings may contribute to the
emerging of the novel multifunction nanomedicine.
This review summarizes much important advancement
about endocytosis mechanisms and the subsequent intracel-
lular fate of nanomedicines. We will focus on the cellular
uptake and intracellular route in different type of endocytosis
pathways, the tools used to confirm the specific endocytic
pathway, and the effect of physicochemical properties of
particles and cell types on the selection of the endocytic
routes. In addition, some meaningful implications about
rational nanomedicine design depending on endocytosis are
also introduced in separate paragraphs. The review may
provide new thoughts for the design of novel multifunctional
nanomedicine and will be helpful to related workers.2. Endocytic pathways for nanomedicines to
enter cells
Endocytosis is themajor route for nanomedicines to transport
across the membrane (Fig. 1). It is generally classified into
phagocytosis and pinocytosis. Phagocytosis was originally
discovered in macrophages. Pinocytosis is present in all types
of cells in four forms, such as clathrin-dependent endocytosis,
caveolae-dependent endocytosis, macropinocytosis, and cla-
thrin- and caveolae-independent endocytosis [3,4].
2.1. Phagocytosis
Phagocytosis is a special endocytic pathway predominantly
occurred in phagocytes, such asmacrophages, neutrophils and
monocytes [5]. Relatively, large particles aremore likely to take
this way. Nanoparticles which adopt this way of entry into
cells need to be recognized by the opsonin firstly, such as
immunoglobulin (IgG and IgM), complement component (C3,
C4, and C5) and blood serum proteins. Thereafter, theopsonized nanoparticles bind to the cell surface and interact
with the receptor, inducing the cup-shaped membrane
extension formation. The membrane extensions enclose the
nanoparticles and then internalize them, forming the phag-
osomes which have a diameter of 0.5e10 mm. Finally, the
phagosomes move to fuse with lysosomes [5,6]. But the cargo
contained in the phagosomeswill be destroyed by acidification
and enzymolysis in the lysosomes. Therefore, to produce
desired effects, nanomedicinesmust bypass this route to avoid
degradation.
2.2. Pinocytosis
Pinocytosis is a major route for the cells to drink fluid, solutes
and suspensions containing small particles. It is classified
to clathrin-dependent endocytosis, caveolae-dependent
endocytosis, macropinocytosis and clathrin- and caveolae-
independent endocytosis, based on the proteins involved in
the pathways [3,4].
2.2.1. Clathrin-dependent endocytosis
Clathrin-dependent endocytosis is present in all mammalian
cells, occupying an important part in cellar entry. After
nanomaterials interact with receptors on the cytomembrane,
a kind of cytosolic protein named clathrin-1 polymerizes on
the cytosolic side of the plasma where the cargo is internal-
ized [4]. After wrapping the nanoparticles inside, the vesicle is
pinched off through the GTPase activity of dynamin, forming a
clathrin coated vesicles (CCV) [7]. With energy supplied by
actin, CCVs move towards inside the cells, and the route is
regulated by the cytoskeleton [8]. The clathrin coat is shed off
in the cytosol. Where is the destination of the vesicles? It may
be associated with the receptor that nanoparticles’ ligands
attach to. For example, low-density lipoprotein particles are
internalized through LDL receptor and transferred to lyso-
somes for degradation; while, iron-loaded transferrin is
engulfed via transferrin receptor and recycled to the cell
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other factors, such as chlorpromazine, a hypertonic medium
or potassium depletion [10,11].
2.2.2. Caveolae-dependent endocytosis
Caveolae-dependent endocytosis is also a common cellular
entry pathway. It could bypass lysosomes [9], thus many
pathogens including viruses and bacteria select this way to
avoid lysosomal degradation [12]. For the same reason, this
route is believed to be beneficial for enhancement of con-
centration of targeting position and improvement of thera-
peutic effect. In this pathway, caveolin, a protein exist inmost
cells, plays a dominate role. There are three isoforms of cav-
eolin in mammalian cells. Caveolin-3 is muscle specific, while
caveolin-1 and -2 are abundant in most nonmuscle cells (such
as endothelial cells, fibroblasts and adipocytes) and absent in
neurons and leukocytes [9]. By binding to the receptors on the
plasma membrane, nanoparticles or pathogens, like Simian
virus 40 [13] and cholera toxin [14], can interact with the re-
ceptors to induce the formation of the flask-shaped vesicles,
which are cut off from the membrane by dynamin. Similar to
clathrin-dependent endocytosis, caveolar vesicles require
actin tomove and intactmicrotubules to trafficwithin the cell.
The caveolae vesicles traffic to fuse with caveosomes or
multivesicular bodies (MTV) which have a neutral pH [15]. The
caveosomes containing nanomedicine move along with mi-
crotubules to the ER [13,14]. It is thought that nanomaterials in
ER penetrate into the cytosol, and then enter nuclear via the
nuclear pore complex [16]. Compared to clathrin-dependent
endocytosis, this pathway takes longer time and has smaller
vesicles in the process [17]. According to those described
above, nanomaterials taking this way in some certain avoid a
degradative fate and enhance the delivery to a target organelle
(such as ER or nucleus), which is critical for improvement of
therapeutic delivery [13].
2.2.3. Macropinocytosis
Macropinocytosis is commonly defined as a transient, cla-
thrin- and caveolin-independent, growth factor-induced,
actin-driven endocytosis that internalizes the surrounding
fluid into large vacuoles [9,18]. The cargo absorbed through
this way is nonspecific. Actually, macropinocytosis can be
found in almost all cells with few exceptions, like brain
microvessel endothelial cells. This pathway is generally star-
ted with external stimulations which activate the receptor
tyrosine kinases. The activation of receptor mediates a
signaling cascade that induces the formation of membrane
ruffles. However, according to the form of the ruffles, there are
different mechanisms of the macropinosomes pinched off
from the membrane is different. Circular ruffles are cut off by
the multi-functional GTPase of dynamin. In contrast, the
lamellipodialmacropinosomes separated from themembrane
is free of dynamin. The macropinosomes with a diameter of
0.5e10 mm are distinct from other vesicles that formed in
other pinocytosis. The surrounding fluid and particles can be
internalized into the macropinosomes. In macrophages, after
separating from the membrane, macropinosomes move into
the cytosol and fuse with lysosomes. In contrast, in human
A431 cells, the macropinosomes travel back to the cell surface
of themembrane and release the contents to the extracellularspace. Therefore, the final fate of macropinosomes depends
on the cell type [19].
2.2.4. Clathrin- and caveolae-independent endocytosis
This is a distinct pathway, which relies on cholesterol and
requires specific lipid compositions. According to GTPases
which play a role of regulation in the cellular entry pathway,
the clathrin- and caveolae-independent endocytosis is clas-
sified to Arf6-dependent, Cdc42-dependent and Rhoa-
dependent [19]. Dynamins also play a dominant part in
these ways, while it is not deeply understood. This field draws
more and more attentions, but unfortunately, it is still far
away from deep understanding and need further research.
The involved endocytic apparatus may contain clathrin-
independent carrier (CLIC) or GPI-anchored protein-enriched
early endosomal compartment (GEEC) [9]. Furthermore, their
later stages are not yet clearly identified.3. Study method of the endocytic pathways
The review has introduced the pathways for nanomedicines
entering cell. In this section, we will discuss how to study
these processes and identify certain pathway that nano-
medicines employ. Previous researches usually use endocytic
markers to show the location of the nanomedicine, or use
endocytic inhibitors to confirm whether the corresponding
pathway plays an important role in the uptake of the nano-
medicine. Actually, jointly use the two methods, and the re-
sults will be more convincing.3.1. Markers
There isamethodthatusespropermolecularprobersormarkers
to study the intracellular fate of nanomedicines. Mark the spe-
cific probers ormarkerswhich can showspecific fluorescence or
color on the nanomedicines, the marked nanomedicines in the
intracellular compartments or organelles can be viewed intui-
tively with the help of the confocal imaging technology. It is
important to confirm the destination of the cargo and the
pathway employed by nanomedicines. Additionally, combined
with a three dimensional confocal technology, we can get more
intact information of the whole cell layer by layer [20].
Some classical probers or makers are known to be inter-
nalized through specific endocytic pathway. Low density li-
poprotein (LDL) [21] and transferrin (Tf) [22] enter cells
through clathrin dependent endocytosis (CME), so they are
commonly used as markers of CME. Moreover, cholera toxin
beta subunit (CTBs) [23], Shiga Toxin [24] and even caveolin-1
are usually used as markers of caveolae dependent endocy-
tosis, and dextran is the marker of macropinocytosis [25].
However, thesemarkers are hard to select, and while entering
different cells these markers may use different pathways. For
example, when CTBs enter cells that lack caveolae, they
cannot use caveolae dependent endocytosis, and a series of
electron microscopic assay show that it may be related to a
novel clathrin-independent internalization pathway [26].
Some markers can indicate the destination of the nano-
medicines within cells. Especially, the proteins contained in
specific endocytic vesicles or intracellular organelles, can be
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teins can show the exact position of the nanomedicines in the
cells, like Rab5 in the early endosome [27], Rab7 in the late
endosome [28], the lysosome associated membrane protein
1(LAMP-1) around the lysosome [28], caveolin-1 in caveolae,
endoplasmic reticulum retention signal KDEL of ER [29]. They
can help to solve the problem associatedwith the intracellular
fate of the nanomedicines.
There are also dyes for organelles, such as LysoTracker and
LysoSensor for lysosome [30]. They can be used to detect the
colocalization of lysosome and the labeled nanomedicinewith
the confocal microscope. Apart from the confocal imaging
technology, electronmicroscope and atomic forcemicroscope
also can be used in this area.
3.2. Inhibitors
Inhibitors of endocytosis can be used to block the specific
endocytic pathway to confirm whether it is employed by the
nanomedicines to enter cells. It can be used along with the
markers to confirm the endocytic mechanisms used by the
nanomedicines and achieve a more convincing result. Un-
fortunately, there are some disadvantages for the commonly
used inhibitor tools, either. For example, previous researches
show that the inhibitor of the specific endocytic pathway
always influence on other pathways [31], and the inhibitor
can block different endocytic mechanisms in different cell
types [32]. Some widely used inhibitors and methods related
to inhibition will be introduced in the following paragraph.
As almost all endocytic pathways are energy dependent
processes, they can be inhibited by low temperature and an
ATPase inhibitor (like sodium azide) at the same time [33].
Therefore, the two factors can be used together to distinguish
from the non-endocytic pathways. As respect to the specific
endocytosis mechanisms, hypertonic sucrose (0.4e0.5 M),
chlorpromazine (50e100 mM) and potassium depletion can be
used to inhibit the clathrin dependent endocytosis [34]; methyl-
b-cyclodextrin (MbCD), filipin, nystatin and cholesterol oxidase
can be used as the inhibitors for caveolae dependent endocy-
tosis [35]; amiloride, cytochalasin D and rottlerin can block
macropinocytosis [35]. When an inhibitor is firstly used on the
cell, the concentration of sufficient inhibitory efficiency and
lowest cytotoxicity need to be detected to make sure a proper
concentration to be used in the experiments.
Apart from inhibitors, mutants which lack of the protein
involved in a specific endocytic pathway, like knock-out cell
lines [36], also can be used to exclude or verify specific endo-
cytic pathways for nanomedicines. This method is becoming
increasingly popular.Fig. 2 e Nanoparticles which possess different charge or no
internalization into cells. a) Cationic particles strongly
interact with the membrane and enter cells rapidly. b)
Anionic particles bind the positive site at themembrane and
enter cells. c) Neutral nanoparticles also can get into cells.
Two different neutral particles will be showed in Fig. 3.4. Effect factors of endocytosis pathway
selection
Different endocytic pathway varies in the protein involved,
the size of the formed vesicles and the cell type where they
were found. After engulfed, the intracellular fate of the
nanoparticles is dependent upon the selected endocytic
pathway. Modern drug delivery systems pay more attention
on the nanoparticles’ intracellular travel. A growing numberof researches show that the selection of nanomaterials
transport pathway was affected by the physicochemical
characteristics of nanoparticles (size, charge, shape, etc.) and
the different endocytic machinery in various cell type [3,4,6].
But, in fact, in the studies of diversified nanoparticles and cell
models, there is no common factor. In this paper, we will take
an attempt to present these factors and make recommenda-
tions for the design of drugs in the future.
4.1. Size
In the endocytic process, the size of the vesicles that contain
nanoparticles varies with the specific pathway. It has always
been believed that the size of nanoparticles may be a
considerable factor that affects which pathway will be
employed by the nanoparticles [37]. Firstly, keep the particles
small enough to enter the vesicles, and the size range from
10 nm to 500 nmand limited up to 5 mm. The large particles are
most likely to be engulfed via macropinocytosis. The size of
vesicle involved in clathrin mediated endocytosis is about
100 nm, while the size involved in caveolae mediated endo-
cytosis is about 60e80 nm [9]. On the other hand, some re-
searchers suggest that the size may not be that important
compared to other factors in the pathway selection of nano-
particles entry into cells [38]. But it is understandable that the
small particles may be beneficial to enter the cells rapidly.
4.2. Surface charge
It is known that the cytomembrane possess negative charge
[39]. Therefore, the cationic nanoparticles may show a strong
electrostatic interaction with the cells, which result in a rapid
entry (Fig. 2). It’s worth mentioning that positively charged
nanoparticles can escape from endosomes after internaliza-
tion and exhibit perinuclear localization because of the ‘pro-
ton-sponge’ effect. The nanoparticles without any charge at
physiological pH may interact with the cells with the aid of
hydrophobic and hydrogen bond interactions [40]. Addition-
ally, neutral particles coated with hydrophilic polymers can
Fig. 4 e The effect of particle shape on phagocytosis. U is
defined as the angle between the membrane normal at the
point of attachment and the line defining the particle
curvature at this point. Particles are internalized
successfully at U £ 45; the internalization of particles can
be inhibited at U> 45.
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absorption. The anionic nanoparticles may be endocytosed
through the interactionwith the positive site of the proteins in
membrane, and they can be highly captured by cells because
of their repulsive interactions with the negatively charged cell
surface [41]. Is the charge a parameter to determine which
trafficking pathway will be chosen? It seems confused. For
cationic nanoparticles, the majority of the reports indicated
they mainly enter cells through CME [42,43], while some
others show that they utilize macropinocytosis [44] or cav-
eolae- and clathrin-independent endocytosis [45] or even
multiple pathways including caveolae mediated endocytosis
[46]. The anionic nanoparticles are more likely to use
caveolae-dependent endocytosis [45], but there are also some
exceptions [47]. In addition, the neutral nanoparticles showno
clear preference for specific routes.
4.3. Surface hydrophobicity
Hydrophobic nanoparticles have higher affinity for the cell
membrane than hydrophilic ones, leading to an improvement
of cell uptake in the kinetics and the amount (Fig. 3). Hydro-
philic polymers used to modified nanoparticles, such as poly-
ethylene glycol (PEG) [48e50], poly (N-vinyl-2-pyrrolidone)
(PVP) [51], poly(aminoacids) [52] anddextran [53], forma ‘cloud’
to suppress the interactionbetweenthenanoparticlesand lipid
bilayer of cells.On theotherhand, it canprolongnanoparticles’
life in blood to reach specific site. The chemical composition at
the surface nanoparticles determines the surface hydropho-
bicitywhichcanpromoteorsuppress the interactionwithcells,
thereby influencing the route of cell uptake. It is worth noting
that the kinds of polymer used in the formation of nano-
particles may contribute to the route selection.
4.4. Shape
Precious experimental studies have discovered the role of the
particle shape in drug delivery, but these mainly focus on
phagocytosis (Fig. 4) [54,55] and there is no specific conclusionFig. 3 e Nanoparticles with different hydrophobicity
present different affinity with the cell membrane.on the pathway selection of nanoparticles. It is notable that
particles with a proper aspect ratio enjoy a perceptible advan-
tage as to internalized rate [56e58]. Moreover, a particle fabri-
cation technique called PRINTmay be extensively applied in the
preparation of nanoparticles with needed size or shape [59].
4.5. Cell type
If the cells have no necessary proteins involved in the specific
endocytic pathway, it is easy to understand that the endocytic
pathway cannot be adopted by this kind of cells. For example,
HepG2 cells have no endogenous caveolin, so they are unable
to uptake nanoparticles by caveolae mediated endocytosis [60].
In addition, the growing environment of cells, such as cell
density and hormones, may affect the phenotype of cell and
further affect the endocytic pathway. Notably, there are distinct
differences between normal cells and tumor cells, and it is
promising to target the tumor based on the different endocytic
pathway [61]. However, the current studies fail to focus on the
connection between the cell origin and the endocytic pathways.
It is necessary to supply a gap in this area.
In fact, all factors work jointly to result in the selected
pathway. These factors make their contribution in union to
defining nanoparticles’ entry into cells and final destination in
cells, and it is better to consider these factors as far as possible
in design of the desired nanoparticles.5. Implication for rational design of
nanomedicines
There are many interesting phenomena associated with the
endocytosis of nanomedicines within our bodies. Some of
them enlighten us on rational design of nanoparticles. Next,
we will introduce them.
5.1. Transcytosis
The medicine is believed to perform well only if it can be
delivered to specific organs or cells. For orally preparations,
they need to travel across the epithelial cells in gastrointes-
tinal tract and get into blood vessels. But this is not the end.
They canwork unless they traffic across the vessel endothelial
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Transcytosis play a critical role in these processes. Fromabove
we know that nanoparticles which take caveolae-dependent
endocytosis can bypass the lysosomes and avoid the degra-
dation compared with classic clathrin-dependent endocytosis
and other endocytic pathways. After that, the cargo could be
released to extracellular matrix. Therefore, the transcytosis of
nanoparticles is predominantly mediated by the caveolae,
which is determined by the property of caveolae-mediated
endocytic pathway [62]. Literature have revealed that cla-
thrin also participate in the transcytosis, but its contribution is
less than 1% [63].
Caveolae-mediated transcytosis can be thought in three
steps (Fig. 5) [64]. It starts with the formation of the separate
caveolae pinched off from the membrane, in short, endocy-
tosis. Following, the caveolae traffic through cytoplasm.
Finally, the free caveolar vesicles dock and fuse with specific
membranes to release the cargo into the perivascular space,
and this process may rely on the presence of members of
SNARE complex [65].
The particular character and function of caveolae make
itself be an ideal drug target. It has the potential therapeutic
value that increasing the absorption of drugs and accumula-
tion in specific site by enhancing transport through the
epithelial or endothelial cells. As an obvious obstacle, endo-
thelial cells can forbidmanymaterials from circular blood into
underlying tissue cells; likewise they can limit the drug to
enter target cells. For example, monoclonal antibody was
promising initially, but it is far away from success in target the
extravascular sites. This is, in part, because it cannot extrav-
asate across the tight and continuous endothelial tissue [64].
In physiology field, specific ligands, modified ligands and an-
tibodies are usually used to target receptor. An accessible
approach to raise uptake of nanomedicines is binding an
antibody which can recognize or target the caveolae to the
nanoparticles [65]. It provides a method to overcome the
barrier of endothelial or epithelial cells for drug and gene de-
livery. We can achieve theoretical expected value in phar-
macokinetics and desired therapeutic effects. Intrinsic
antibodies and peptides of tumors only recognize the antigens
expressed on the surface of the tumor. As a result, they areFig. 5 eModel of caveolae-mediated transcytosis. A) After the fis
This is the first step. B) The formed vesicle is changing. C) v-SNA
second step. D) v-SNARE contacts with t-SNARE at target memb
is released to outside cells. D and E make up the third step.restricted by solid tumors partly because of the barrier formed
by endothelial cells and the increased pressure in tissue space
[66]. The therapeutics which target caveolae at vascular
endothelium can overcome the barrier to deliver into tumors
successfully. The albumin which can be transported from the
luminal to the basal poles of the membrane with the help of
caveolae after binding to its receptor gp60, is a best example
[67]. Paclitaxel that packed in the nanoparticles with albumin
covering can be easily delivered to the tumor tissue after
transcytosis. Compared to control paclitaxel, the increased
antitumor activity and higher intratumoral paclitaxel level
have been conformed according to clinical researches [68].
5.2. A potential method to minimize first past effect of
nanomedicine
The oral administration of macromolecular drug such as
proteins and peptides or nanoparticles is faced with chal-
lenges in drug absorption delivery. Recent researches have
revealed that M cells in the Follicle Associated Epithelium
overlying organized mucosa-associated lymphoid tissues
(Fig. 6A), namely the intestinal Peyer’s patches, may be
necessary in absorption transport of macromolecules and
nanoparticles for oral administration [69,70]. The intestinal
surface area is physically protected by a layer of tightly joined
epithelial cells, which consist of M cells and enterocytes
(Fig. 6B). Compared to enterocytes, M cells are characterized
with fewer lysosomes, more mitochondria, a lack of mucous
glycocalyx covering, poorly organized brush border mem-
brane and a basolateral cytoplasmic invagination that forms a
pocket containing lymphocytes and occasional macrophages
[71,72]. Otherwise, M cells have reduced levels of membrane
hydrolase activity, which can keep the absorbed drug intact
[71]. M cells’ high transcytotic capacity is most remarkable
and interesting. This property indicates that M cells may act
as a highly efficient portal for macromolecular drug, nano-
medicine and mucosal vaccination. M cells can delivery
foreign materials bound to their surface from the intestinal
tract to the underlying lymphoid tissues, such as lymphoid
follicle or lymphatic vessels, where immune response occurs
for vaccine. Studies on polystyrene particles show that thesion mediated by dynamin, the free caveolar vesicle forms.
RE forms at the surface of the vesicle. B and C make up the
rane, and SNARE complex forms. E) The cargo in the vesicle
Fig. 6 e AModel of follicle associated epithelium (FAE). B
Model ofM cells in FAE. (Adapted from the reference [71,72]).
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cles absorbed into the lymphatic vessels, while particles above
1 mm remain entrapped in the peyer’s patches [73].
As for M cells, it is clear that the transport of nano-
medicines is predominantly mediated by endocytosis, an
energy-dependent mechanism, but the question is which
specific mechanism of endocytosis will be employed?
Although the process can be considered as transcytosis, the
caveolae-mediated endocytosis is unlikely to be solely
responsible for M cells [73]. Previous literature in this field
remain controversial. Jae Sung Lim, etc, considered that
caveolin-1 plays a crucial role in the entry of nanoparticles
into M cells, and they found that caveolin-1 has a high level of
expression in M-like cells, while not in caco-2 cells (an intes-
tinal epithelial cell simulatedmodel) [74]. Anne des Rieux, etc,
suggested that nanoparticle endocytosis of M cells is most
likely macropinocytosis [70]. Some other reported that cla-
thrin mediates endocytosis of particles, macromolecules and
microorganisms [75]. Sometimes, phagocytosis also is a
candidate [76]. Therefore, as for M cells everymechanismmay
contributes to the endocytosis of nanoparticles to some
extent. Physicochemical properties of nanoparticles, such
as size, shape, surface potential and hydrophobicity/hydrophilicity balance, etc, may exert their effects on the
mechanism selection of nanoparticles uptake of M cells [73].
M cells are not the only gate for the particulates in the
gastrointestinal tract. However, their relative high trans-
cytotic capacity and intimate relationship with inductive sites
of the mucosal immune system make them to be a perfect
target for strategic delivery of nanoparticles and mucosal
vaccines. Some literature said that the bulk of particle trans-
location occurs in the FAE [73], and M cells began to be the
subject of intense research. As the specific mechanism
employed by M cells is uncertain, it makes little sense to
modify the particles with the ligands to target clathrin or
caveolae, or other associated component. It is a relative
wonderful strategy to decorate nanoparticle surface with
a molecule targeting on M cell, which can enhance their ab-
sorption transport through specific interactions between
nanocarriers and M cells [70,73]. The special interactions
might be non-specific interactions or targeting on M cells by a
specific ligand or both [77]. Studies have attained significant
achievements, such as lectins derived from Sambucus nigra
and Viscum album could label the surface of human FAE [74],
RGD derivatives could target b1 integrin concentrated at the
apical pole of M cells [78], and Claudin 4 highly expressed in
peyer’s patchM cells also could be a site for oral nanoparticles
target delivery [79]. Nanoparticles targeting on M cells could
not only enhance the oral bioavailability but also bypass the
liver and avoid the first pass effect to some extent owing to
their lymphatic delivery. Therefore, the continuous attention
given to M cells is not surprising.
5.3. Organelle target selection
In contemporary drug therapy, most drugs are designed to
target specific sites in the human body. Nevertheless, many
therapeutical sites are located in the cells. Like the nucleus,
the mitochondria or lysosomes, they all require drugs to be
delivered to specific organelles. In ideal circumstances,
nanoparticles as carriers could transfer their payload to spe-
cific tissues, cells, or even cellular organelles. Therefore, the
nanoparticles which can be delivered to specific site may be
an answer for organelle target selection. Nanoparticles take
various endocytic pathways to come into cells, and the way
they employ influences the intracellular fate of the nano-
particles [80]. The intracellular delivery of nanoparticles based
on endocytosis will be discussed in detail in the following part.
Except for caveolae-mediated endocytosis, the other
pathways all have a relationship with lysosomes, and it is a
great idea for drugs to target lysosomes. Enzyme replacement
therapy should had perfect therapeutic effect on lysosomal
storage disease, but the enzyme can be eliminated easily in
the blood circulation, which result in the dramatic decrease of
drug in desired site [81e83]. Encapsulated in the nanocarriers,
the enzyme could be protected from clearance and keep sta-
ble. After endocytosis, the drug will deliver to lysosomes and
produce improved therapeutic effects. While, as regard to
drugs used for other diseases, the lysosomes will be their hell.
These drugs will be entrapped in endosomes and degraded in
lysosomes and lost their activity in the end.
In the process of caveolae-mediated endocytosis, the
nanoparticles do not fusewith lysosomes after their entry into
Table 1 e Overview of strategies based on nanotechnology for organelle targeting mentioned in this article.
Target organelle Strategy Ref.
Lysosomes Increase drug accumulation in lysosomes by load the drug in liposomes [82,83]
Endoplasmic reticulum pH-sensitive liposomes improve therapeutic efficiency [85]
Nanoparticles decorated with ER-targeting peptides [86]
Cytosol Nanoparticles modified with CPPs [89e91]
pH-sensitive nanoparticles enhance endosomal escape [87,88]
Transferrin modified nanoparticles interact with the receptor at the
surface of cell
[92]
Nucleus Nuclear localization signal modified nanoparticles [93]
Nanoparticles modified with CCPs [96]
Mitochondria Mitochondria targeting sequence modified quantum dots [95]
Polymer micelles show mitochondria targeting property [97]
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also give them a chance to arrive other organelles. After
engulfed in the cells, the vesicles containing nanoparticles
fuse with caveosomes or multivesicular body (MTV). There-
after, the payload can be delivered to endoplasmic reticulum
or Golgi complex, or even released to outside the cells [84]. So
the drugs that work by targeting ER or Golgi complex can be
designed to employ caveolae mediated endocytosis. This
strategy may be helpful to increase the accumulation of the
drugs in ER or Golgi apparatus [85,86].
Also, there are still some targets at other organelles need
to be treat, like cytosol, nucleus and mitochondria. How can
we deliver the drugs to that desired sites? As mentioned,
nanoparticles which transferred to ER via caveolae-mediated
endocytosis can penetrate into cytosol and have a chance to
pass through nuclear pore complex and get into nucleus. In
addition, if released from the endosomes, particles could
target the sites at cytosol and other organelles. Literature
show that the application of pH-sensitive polymeric blocks
in nanoparticles design can help the particles to be released
from the endosomes [87,88]. Additionally, nanoparticles that
modified with cell penetrating peptides [89e91] or ligands
which interact with the receptor at the surface of membrane
[92] also could enter cells. To reach the desired organelle
sites, Drugs are still confronted with some barriers, such as
cytoskeletal proteins in cytosol and membrane structure of
target organelle. With the help of signal sequence, like nu-
clear localization sequences [93] and mitochondrial locali-
zation sequences [94,95], drugs can target the appointed
organelle. Additionally, modified nanoparticle [96] or poly-
mer micelles [97] also present organelle target property.
As a new promising approach for optimizing the drug
pharmacological activities, organelle targeted drug delivery will
drawmore attention (Table 1). The different endocytic pathway
and their intracellular fate may enlighten the researchers who
are interested in organelle targeting preparation.6. Conclusion
Nowadays, nanomedicines are increasingly showing its
outstanding advantages in diagnosis and treatment of the
diseases. As for the design of nanomedicines, it is critical to
understand their uptake pathways. We have summarized the
characteristics of the endocytic pathways, the tools to dissect
the specific mechanism and the factors affecting the selectionof pathway employed by nanomedicines. In addition, some
rational designs associated with endocytosis in human body
have been introduced in this review.
Although considerable achievements have been acquired,
this field is still in the infancy. The existing results are mostly
based on the in vitro experiments, so the crux of the research is
to study the complex endocytic process of nanomedicine
entering into cells in vivo. Besides, there are still many
controversial points and unstated field. A deep and elaborate
study on this field is still necessary.
In the near future, organelle target will be a hotspot. Drugs
will be delivered to lesion site in the specific organelles. If so, it
is not difficult to imagine the dose of medication will dramati-
cally decrease. Correspondingly, unwanted adverse effects will
be minimized. In the design of nanocarriers targeting on spe-
cific organelle, researchers will spend much more time on the
study of their intracellular fate. What’s more, everybody looks
forward to applying the designed nanomedicine to treat dis-
eases and achieve desirable therapeutic effect.r e f e r e n c e s
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